Matthew Allaway, DO, Discusses Transperineal Biopsy Approach for Prostate Cancer
Matthew Allaway, DO, detailed benefits of using an emerging transperineal biopsy approach to identify prostate cancer in hard to access areas of a patient’s prostate.
On an episode of Inside the Practice as part of Medical World News, Matthew Allaway, DO, founder and chief executive officer at Perineologic, spoke with CancerNetwork® about a prostate cancer biopsy technique that uses a transperineal approach to better detect cancer in harder to reach areas of the prostate. Along with this, Allaway touched on the American Cancer Society’s annual “Cancer Facts & Figures 2022” report and detailed the important findings from a companion study.
The new technique uses 2 needle sticks compared to 12 sticks with a standard transrectal biopsy. Moreover, the transperineal approach has a reduced risk of complications such as pain, bleeding and urinary retention.
“Historically, the prostate biopsy was performed by placing an ultrasound probe in the patient’s rectum so you could see the prostate. Then, with the probe in that position, you slide a biopsy needle within a needle guide that then passes through the rectal wall to get into the prostate,” Allaway explained regarding standard prostate biopsy techniques.
Reference
Cancer facts & figures 2022. American Cancer Society. 2022. Accessed January 28, 2022. https://tinyurl.com/5rdc6nbc
FDA Expands Indication for Illuccix for PSMA Radioligand Selection in Prostate Cancer
